Company Overview of aTyr Pharma Inc.
aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory d...
3545 John Hopkins Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Executive Chairman and Chief Executive Officer
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.
aTyr Pharma Inc. Key Developments
aTyr Pharma Inc. Announces Executive Changes
Nov 10 15
aTyr Pharma Inc. announced that Melissa Ashlock, M.D., has been promoted to Senior Vice President, Translational Medicine and Therapeutics, from Vice President, Translational Medicine and Therapeutics. Dr. Ashlock has been with aTyr since 2011 and previously served as the Vice President of Drug Discovery for the Cystic Fibrosis Foundation (CFF), where she was the program leader for multiple CFF-funded collaborative drug discovery programs with industry, including Kalydeco. Ashraf Amanullah, Ph.D., has been appointed Vice President, Manufacturing. Dr. Amanullah most recently served as Senior Director at Gilead Sciences, where he oversaw the cell line development, drug substance, analytical development, potency, stability, QC and formulation, drug product and device development functions as well as external drug substance and drug product manufacturing. Prior to joining Gilead, he was Director of Process Development at Genentech. John T. Blake, C.P.A., has been promoted to Vice President, Finance. Mr. Blake had served as Senior Director, Finance, and Controller of aTyr since March 2015. Prior to joining the Company, Mr. Blake served as Director, Financial Planning and Analysis, of Volcano Corporation.
aTyr Pharma Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 10 15
aTyr Pharma Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company announced loss from operations of $11,313,000 compared to $6,231,000 for the same period a year ago. Net loss was $11,329,000 compared to $6,631,000 for the same period a year ago. Net loss attributable to common stockholders was $11,329,000 compared to $6,770,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.48 compared to $8.02 for the same period a year ago.
For the nine months, the company announced loss from operations of $31,133,000 compared to $17,524,000 for the same period a year ago. Net loss was $31,480,000 compared to $18,312,000 for the same period a year ago. Net loss attributable to common stockholders was $31,495,000 compared to $18,728,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $2.38 compared to $22.73 for the same period a year ago.
aTyr Pharma, Inc. Initiates Phase 1b/2 Clinical Trial in Patients with Early Onset FSHD
Nov 9 15
aTyr Pharma Inc. announced the continued expansion of its Resolaris clinical program in rare myopathies with an immune component by initiating a Phase 1b/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 clinical trial in early onset FSHD is an international multi-center, open-label, intra-patient dose escalation study designed to assess the safety, tolerability, immunogenicity, and biological activity of Resolaris. Clinical trial sites are preparing to screen patients for inclusion in the study and are expected to enroll up to 16 early onset FSHD patients who displayed signs or symptoms of the disease prior to 10 years of age. In the first stage of the trial, up to eight patients between the ages of 16 and 25 years will be enrolled. The second stage of enrollment is expected to include up to eight patients between the ages of 12 and 15 years. The early onset FSHD clinical research program, which will involve both young adults and children, is in addition to the Company's recently initiated Phase 1b/2 clinical trial in limb girdle muscular dystrophy (LGMD2B) and the ongoing Phase 1b/2 clinical trial evaluating Resolaris in adult patients with FSHD. All three trials, adult FSHD, early onset FSHD and LGMD2B, will assess Resolaris' impact on the immune component of the disease using blood borne markers and magnetic resonance imaging (MRI) of skeletal muscle.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 31, 2015